Supernus Pharmaceuticals Inc (SUPN) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $55.75
• Market Cap: $3.23B
• EPS: $-0.36
• 52-Week High: $59.68
• 52-Week Low: $29.16

Market Sentiment

Supernus Pharmaceuticals Inc currently has a Bullish sentiment score of 0.16.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system disorders, particularly in the United States. Based in Rockville, Maryland, Supernus specializes in addressing unmet medical needs in epilepsy and migraine, supported by a promising pipeline aimed at improving patient outcomes. With a commitment to enhancing quality of life for affected individuals, the company operates in a rapidly e...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Supernus Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does SUPN pay dividends?

Supernus Pharmaceuticals Inc (SUPN) does not currently pay a regular dividend.

What is SUPN's market cap?

Supernus Pharmaceuticals Inc (SUPN) has a market capitalization of $3.23B with a current stock price of $55.75.